Division News

Fowler part of collaborative research team looking at multidrug resistant bacteria

Vance Fowler, MD, MHS, professor of medicine (Infectious Diseases), is part of a research team funded by Duke Translational Medicine Institute and the Duke CTSA that is exploring the efficacy of beating back multidrug resistant bacteria by using chemical compounds known as LpxC inhibitors. These chemical compounds disrupt the formation of Lipid A in the protective membranes around Gram negative bacteria - a novel way of destroying bacteria.

Perfect awarded 5-year program project grant from NIAID

John Perfect, MD, professor of medicine and chief of the Division of Infectious Diseases, received notification today from the National Institute of Allergy and Infectious Diseases of a program project award (P01) for his proposal entitled “Transdisciplinary Program to Identify Novel Antifungal Targets and Inhibitors."  This award, effective 6/25/15, will last five years and, with its cores, total $9,277,000.

Duke Human Vaccine Team awarded $5 million to study fungal fever

The Duke Human Vaccine Institute’s Vaccine and Treatment Evaluation Unit has been awarded a $5 million contract from the National Institute of Allergy and Infectious Disease to support further research on Valley Fever Pneumonia.

Valley Fever Pneumonia is caused by the fungal pathogens Coccidioides posadasii and Coccidioides immitis, which primarily live in soil. Valley Fever is endemic in certain parts of the southwestern United States, including Arizona and California.

Prudhomme-O'Meara receives supplemental Duke CTSA award

Wendy Prudhomme-O'Meara, PhD, assistant professor of medicine (Infectious Diseases) and global health, has received a supplemental award through Duke Translational Research. The award will provide supplemental funding for the project "Novel mHealth platform to ensure quality of community-based malaria diagnosis."

The research evaluates an innovative public-private partnership in Kenya using trained community health workers to target malarial medicines to those with confirmed malaria infection.